Omeros (OMER) Expected to Announce Earnings on Tuesday

Omeros (NASDAQ:OMER) is anticipated to announce its Q4 2025 results after the market closes on Tuesday, March 3rd. Analysts expect the company to announce earnings of ($0.57) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

Omeros Stock Down 5.0%

Shares of Omeros stock opened at $11.44 on Tuesday. The firm has a market cap of $811.10 million, a price-to-earnings ratio of -5.66 and a beta of 2.45. Omeros has a 52-week low of $2.95 and a 52-week high of $17.65. The company’s 50-day simple moving average is $12.42 and its 200-day simple moving average is $8.50.

Insiders Place Their Bets

In other Omeros news, CAO David J. Borges sold 30,000 shares of the stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total transaction of $369,300.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 12.90% of the company’s stock.

Hedge Funds Weigh In On Omeros

Institutional investors have recently added to or reduced their stakes in the business. Schonfeld Strategic Advisors LLC acquired a new position in Omeros during the fourth quarter worth approximately $218,000. Rafferty Asset Management LLC purchased a new stake in shares of Omeros during the 4th quarter valued at $210,000. XTX Topco Ltd acquired a new stake in shares of Omeros during the 2nd quarter worth $191,000. Abel Hall LLC acquired a new stake in shares of Omeros during the 4th quarter worth $176,000. Finally, Osaic Holdings Inc. raised its position in shares of Omeros by 34.6% in the 4th quarter. Osaic Holdings Inc. now owns 7,547 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 1,938 shares during the period. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Wall Street Zen lowered Omeros from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. HC Wainwright upped their target price on shares of Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a research report on Thursday, January 22nd. Finally, D. Boral Capital reissued a “buy” rating and set a $36.00 price target on shares of Omeros in a research note on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Omeros presently has an average rating of “Moderate Buy” and an average price target of $40.33.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.